Continuation Trial Evaluating the Tolerability and Activity of FK228 in Patients That Completed Prior Study With FK228

NCT00106301 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

2

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Renal Cell
Prostatic Neoplasms

Interventions

DRUG: FK228 (romidepsin)

Sponsor

Celgene